Vita Life Sciences Past Earnings Performance
Past criteria checks 5/6
Vita Life Sciences has been growing earnings at an average annual rate of 8%, while the Pharmaceuticals industry saw earnings growing at 5.8% annually. Revenues have been growing at an average rate of 12.4% per year. Vita Life Sciences's return on equity is 18.6%, and it has net margins of 11.2%.
Key information
8.03%
Earnings growth rate
6.49%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.22% |
| Revenue growth rate | 12.38% |
| Return on equity | 18.56% |
| Net Margin | 11.19% |
| Last Earnings Update | 31 Dec 2025 |
Recent past performance updates
Recent updates
Vita Life Sciences (ASX:VLS) Is Due To Pay A Dividend Of A$0.045
Vita Life Sciences Limited ( ASX:VLS ) has announced that it will pay a dividend of A$0.045 per share on the 3rd of...Weekly Picks: 💊 VLS' Solvable Headwinds, VOS' Multi-Year Growth, and ISRG's Valuation Concerns
Why Vita Life Science’s is a solid business with solvable headwinds, how 2 massive tailwinds will drive multi-year growth for Vossloh, and why Intuitive Surgical’s strengths don’t outweigh the valuation risks.
Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges
Vita Life Sciences (ASX: VLS) – A Solid Business Seeking Renewed MomentumVita Life Sciences (ASX: VLS) is a well-established healthcare company specializing in the formulation, packaging, distributionImproved Earnings Required Before Vita Life Sciences Limited (ASX:VLS) Shares Find Their Feet
When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") above 20x, you may consider...Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough
Vita Life Sciences Limited's ( ASX:VLS ) price-to-earnings (or "P/E") ratio of 14.3x might make it look like a buy...Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035
Vita Life Sciences Limited ( ASX:VLS ) has announced that it will pay a dividend of A$0.035 per share on the 4th of...Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market
Vita Life Sciences Limited ( ASX:VLS ) shares have continued their recent momentum with a 26% gain in the last month...Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06
Vita Life Sciences Limited ( ASX:VLS ) will increase its dividend from last year's comparable payment on the 12th of...Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year
The board of Vita Life Sciences Limited ( ASX:VLS ) has announced that the dividend on 12th of April will be increased...A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)
Today we will run through one way of estimating the intrinsic value of Vita Life Sciences Limited ( ASX:VLS ) by...Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?
The simplest way to invest in stocks is to buy exchange traded funds. But investors can boost returns by picking...Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?
Vita Life Sciences' (ASX:VLS) stock up by 8.5% over the past three months. Given that stock prices are usually aligned...Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?
Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. That said, the...Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
With its stock down 8.3% over the past month, it is easy to disregard Vita Life Sciences (ASX:VLS). But if you pay...Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares
With a price-to-earnings (or "P/E") ratio of 9.7x Vita Life Sciences Limited (ASX:VLS) may be sending bullish signals...Revenue & Expenses Breakdown
How Vita Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 93 | 10 | 42 | 0 |
| 30 Sep 25 | 89 | 10 | 40 | 0 |
| 30 Jun 25 | 86 | 9 | 39 | 0 |
| 31 Mar 25 | 83 | 9 | 37 | 0 |
| 31 Dec 24 | 80 | 9 | 35 | 0 |
| 30 Sep 24 | 79 | 9 | 34 | 0 |
| 30 Jun 24 | 78 | 9 | 33 | 0 |
| 31 Mar 24 | 76 | 9 | 32 | 0 |
| 31 Dec 23 | 73 | 9 | 30 | 0 |
| 30 Sep 23 | 71 | 8 | 30 | 0 |
| 30 Jun 23 | 69 | 7 | 29 | 0 |
| 31 Mar 23 | 68 | 7 | 29 | 0 |
| 31 Dec 22 | 67 | 7 | 29 | 0 |
| 30 Sep 22 | 65 | 8 | 27 | 0 |
| 30 Jun 22 | 64 | 8 | 26 | 0 |
| 31 Mar 22 | 61 | 8 | 25 | 0 |
| 31 Dec 21 | 57 | 8 | 24 | 0 |
| 30 Sep 21 | 54 | 8 | 23 | 0 |
| 30 Jun 21 | 50 | 7 | 22 | 0 |
| 31 Mar 21 | 48 | 6 | 22 | 0 |
| 31 Dec 20 | 46 | 6 | 21 | 0 |
| 30 Sep 20 | 46 | 6 | 22 | 0 |
| 30 Jun 20 | 45 | 5 | 22 | 0 |
| 31 Mar 20 | 44 | 4 | 23 | 0 |
| 31 Dec 19 | 42 | 3 | 23 | 0 |
| 30 Sep 19 | 42 | 2 | 23 | 0 |
| 30 Jun 19 | 41 | 2 | 23 | 0 |
| 31 Mar 19 | 41 | 2 | 22 | 0 |
| 31 Dec 18 | 41 | 2 | 21 | 0 |
| 30 Sep 18 | 40 | 3 | 21 | 0 |
| 30 Jun 18 | 40 | 4 | 21 | 0 |
| 31 Mar 18 | 38 | 3 | 20 | 0 |
| 31 Dec 17 | 37 | 3 | 20 | 0 |
| 30 Sep 17 | 37 | 3 | 20 | 0 |
| 30 Jun 17 | 37 | 3 | 20 | 0 |
| 31 Mar 17 | 38 | 3 | 20 | 0 |
| 31 Dec 16 | 38 | 3 | 20 | 0 |
| 30 Sep 16 | 38 | 4 | 20 | 0 |
| 30 Jun 16 | 38 | 5 | 20 | 0 |
| 31 Mar 16 | 39 | 5 | 21 | 0 |
| 31 Dec 15 | 39 | 4 | 21 | 0 |
| 30 Sep 15 | 38 | 4 | 20 | 0 |
Quality Earnings: VLS has high quality earnings.
Growing Profit Margin: VLS's current net profit margins (11.2%) are higher than last year (11%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VLS's earnings have grown by 8% per year over the past 5 years.
Accelerating Growth: VLS's earnings growth over the past year (18.8%) exceeds its 5-year average (8% per year).
Earnings vs Industry: VLS earnings growth over the past year (18.8%) exceeded the Pharmaceuticals industry -17.4%.
Return on Equity
High ROE: VLS's Return on Equity (18.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/17 08:44 |
| End of Day Share Price | 2026/07/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vita Life Sciences Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shane Storey | Canaccord Genuity Historic (Wilsons Advisory and Stockbroking Ltd. |